Abstract
The treatment of Barrett's esophagus is controversial. Current treatments include endoscopic therapy, surgical procedures, gastric acid-suppressive therapy with proton pump inhibitors (PPIs), and cancer chemoprevention such as nonsteroidal anti-inflammatory drugs. Endoscopic therapy combined with gastric acid suppressive therapy can result in squamous reepithelialization of the Barrett's mucosa. Antireflux surgery and PPIs therapy are potential options for the treatment of gastroesophageal reflux symptoms in patients with Barrett's esophagus. But there are no prospective studies that support any alternative approach to treatment. Although chemoprevention therapy may reduce cancer risk in Barrett's esophagus, no randomized controlled trials that prove its efficacy have been reported.
MeSH terms
-
2-Pyridinylmethylsulfinylbenzimidazoles
-
Adenocarcinoma / etiology
-
Adenocarcinoma / prevention & control
-
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
-
Barrett Esophagus / therapy*
-
Cyclooxygenase 2
-
Cyclooxygenase 2 Inhibitors
-
Cyclooxygenase Inhibitors / therapeutic use
-
Digestive System Surgical Procedures / methods
-
Enzyme Inhibitors / therapeutic use
-
Esophageal Neoplasms / etiology
-
Esophageal Neoplasms / prevention & control
-
Esophagitis, Peptic / therapy
-
Esophagoscopy
-
Esophagus / surgery
-
Humans
-
Lansoprazole
-
Membrane Proteins
-
Nitrobenzenes / therapeutic use
-
Omeprazole / analogs & derivatives
-
Omeprazole / therapeutic use
-
Prostaglandin-Endoperoxide Synthases / physiology
-
Proton Pump Inhibitors
-
Sulfonamides / therapeutic use
Substances
-
2-Pyridinylmethylsulfinylbenzimidazoles
-
Anti-Inflammatory Agents, Non-Steroidal
-
Cyclooxygenase 2 Inhibitors
-
Cyclooxygenase Inhibitors
-
Enzyme Inhibitors
-
Membrane Proteins
-
Nitrobenzenes
-
Proton Pump Inhibitors
-
Sulfonamides
-
Lansoprazole
-
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide
-
Cyclooxygenase 2
-
PTGS2 protein, human
-
Prostaglandin-Endoperoxide Synthases
-
Omeprazole